<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/43ECF77B-CD97-49C9-812D-40CB69D1D03B"><gtr:id>43ECF77B-CD97-49C9-812D-40CB69D1D03B</gtr:id><gtr:name>San Raffaele Hospital</gtr:name><gtr:address><gtr:line1>29 Via Prinetti</gtr:line1><gtr:region>outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/690ECCF2-F290-4AE0-82CC-F5507E8EDC7E"><gtr:id>690ECCF2-F290-4AE0-82CC-F5507E8EDC7E</gtr:id><gtr:name>Agency for Science, Technology and Research (A*STAR)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Immunology and Molecular Pathology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/43ECF77B-CD97-49C9-812D-40CB69D1D03B"><gtr:id>43ECF77B-CD97-49C9-812D-40CB69D1D03B</gtr:id><gtr:name>San Raffaele Hospital</gtr:name><gtr:address><gtr:line1>29 Via Prinetti</gtr:line1><gtr:region>outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/690ECCF2-F290-4AE0-82CC-F5507E8EDC7E"><gtr:id>690ECCF2-F290-4AE0-82CC-F5507E8EDC7E</gtr:id><gtr:name>Agency for Science, Technology and Research (A*STAR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/74389446-0D26-451F-BC60-01028C798AAD"><gtr:id>74389446-0D26-451F-BC60-01028C798AAD</gtr:id><gtr:firstName>Mala</gtr:firstName><gtr:otherNames>Kunti</gtr:otherNames><gtr:surname>Maini</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801213"><gtr:id>0C19A753-D34F-49C2-857C-5BED651150D3</gtr:id><gtr:title>Bim-mediated attrition of virus-specific CD8 T cells in chronic HBV infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801213</gtr:grantReference><gtr:abstractText>Hepatitis B virus remains one of the top ten killers in the world today, causing around a million deaths every year from chronic liver disease, leading to liver failure and liver cancer. There is a vaccine to prevent spread, but this is of no use to the 400 million people estimated to already be chronically infected. There are now a number of drugs available to treat hepatitis B infection but these typically only suppress the virus rather than clear it; when the patient stops the treatment the virus level comes back up. 
The goal of the work proposed here is to allow us to develop a type of treatment supplement to boost immune control, such that costly and potentially toxic antiviral drugs would only need to be given for a short period. We will address this by parallel experiments using both a mouse model and also cells studied directly from patients, including those on the latest treatments available for hepatitis B virus infection. We have identified a critical defect in T cells (a key type of killer immune cell), which could account for their failure to control hepatitis B virus in patients with chronic infection. We have found that their T cells are triggered to commit suicide when they encounter hepatitis B virus; too few of these cells then survive to control the infection. This proposal aims to work out what drives this cell suicide and whether it can be safely blocked to allow a recovery of T cells. This could then switch the immune response back to the successful type seen in people who manage to control this infection naturally without requiring drug treatment.</gtr:abstractText><gtr:technicalSummary>Persistent infection with hepatitis B virus (HBV) continues to account for more than a million deaths a year worldwide from liver cirrhosis and hepatocellular carcinoma. Existing therapies usually suppress rather than cure infection, necessitating long-term maintenance use of drugs with ongoing limitations of cost, viral resistance and toxicity. There is therefore a pressing need to complement antiviral therapy with a targeted immunotherapeutic approach aiming to restore effective immune control of HBV and achieve sustained off-treatment responses. 
CD8 T cells are known to be critical to the control of HBV and are markedly depleted in patients with persistent infection. We have identified a dysregulated apoptotic pathway in these cells that contributes to their attrition. The pro-apoptotic protein Bim (Bcl-2-interacting mediator) was found to be upregulated in HBV-specific CD8 T cells in patients with chronic compared to resolved HBV infection; downstream inhibition of this pathway rescued HBV-specific CD8 directly ex vivo (Lopes et al JCI May 2008). We hypothesise that blocking Bim-mediated apoptosis will allow successful reconstitution of HBV-specific CD8 T cells able to control infection. 
The underlying mechanism responsible for the induction of Bim in HBV-specific CD8 may be related to excessive TCR triggering, to presentation of antigen by infected hepatocytes, or to cross-presentation of HBV antigens. We will investigate in vitro the contribution of each of these processes to triggering this pro-apoptotic pathway in HBV-specific CD8. We will also address the role of aberrant 41BB signalling and any potential to counteract Bim-mediated apoptosis by correcting this. We will use this experimental set-up to explore the potential to block the induction of Bim using immunosuppressive or non-immunosuppressive cyclophilin inhibitors.
To determine the contribution of Bim-mediated apoptosis to loss of the HBV-specific response in vivo, we will use transgenic mice that replicate HBV at high levels in the liver. When HBV-specific CD8 are infused into these mice they are known to undergo premature death; we will investigate whether this is mediated through the Bim pathway using Bim knockout mice. 
Finally we will examine whether current treatment regimes for chronic HBV infection have any impact on Bim-mediated apoptosis of HBV-specific CD8.
By identifying underlying triggers and testing the potential of blocking approaches in vitro and in vivo, this work will inform future targeted therapeutic interventions to re-programme the pro-apoptotic defect of HBV-specific CD8 T cells.</gtr:technicalSummary><gtr:fund><gtr:end>2013-05-10</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-05-11</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>521183</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Barts and The London School of Medicine and Dentistry</gtr:department><gtr:description>Collaboration with Barts and the London</gtr:description><gtr:id>F16FC382-6DC8-465E-9793-E23C2E5A8575</gtr:id><gtr:impact>Peppa et al PLoS Pathogens 2010</gtr:impact><gtr:outcomeId>FngoLE6CXMz-1</gtr:outcomeId><gtr:partnerContribution>Provision of liver biopsy material for analysis of intrahepatic lymphocytes</gtr:partnerContribution><gtr:piContribution>Analysis of intrahepatic NK cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Medicine</gtr:department><gtr:description>Investigating immunosensececence of T cells in viral hepatitis</gtr:description><gtr:id>02E475BB-4323-44D9-8B8A-E5D0806EBB0F</gtr:id><gtr:impact>Publication by Hoare et al, J Hepatol 2010</gtr:impact><gtr:outcomeId>XFH4MhFVv7G-1</gtr:outcomeId><gtr:partnerContribution>Collaboration on investigating senescent immune responses in livers of HBV patients</gtr:partnerContribution><gtr:piContribution>Expertise in methodology for analysis of replicative senescence of T cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Agency for Science, Technology and Research (A*STAR)</gtr:collaboratingOrganisation><gtr:country>Singapore, Republic of</gtr:country><gtr:description>Redirecting the specificity of T cells in HBV</gtr:description><gtr:id>21F5C92B-D1E5-43DE-8AC7-3C7E2490921E</gtr:id><gtr:impact>Joint grant MRC/A* Star funding</gtr:impact><gtr:outcomeId>DD4C6D42BE6-1</gtr:outcomeId><gtr:partnerContribution>Expertise and new reagents to examine T cell tolerance in HBV</gtr:partnerContribution><gtr:piContribution>Collaborating on investigating ways of overcoming T cell tolerance in HBV</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>San Raffaele Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>San Raffaele Scientific Institute (SRSI)</gtr:department><gtr:description>Role of Bim in HBV transgenic mice</gtr:description><gtr:id>59923ABE-00B3-476A-8485-61C4425381E4</gtr:id><gtr:impact>New animal model/reagent available: Bim knockout HBV-specific CD8 in HBV transgenic mouse
NEw scientific findings, not yet published</gtr:impact><gtr:outcomeId>pXUeNWWePTb-1</gtr:outcomeId><gtr:partnerContribution>Confirming the role of the pro-apoptotic moleucule Bim in limiting survival of CD8 T cells in the setting of HBV replication using T cells from Bim knockout mice transferred to HBV transgenic mice.</gtr:partnerContribution><gtr:piContribution>Original work in humans pointing to the importanc eof this pathway. Co-designed the experiments and co-supervising the work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>52000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EASL Entry level fellowship</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>European Association for the Study of the Liver (EASL)</gtr:fundingOrg><gtr:id>7E4BA30F-28AD-4111-A075-CFCBB8932493</gtr:id><gtr:outcomeId>14E9A8E8BC50</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/A*Star Singapore joint initiative</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>37D32AF9-D085-4C9A-9196-75BF2111109F</gtr:id><gtr:outcomeId>8C472B2B70C0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>3877D953-806E-4038-8E4D-FEE802167D2E</gtr:id><gtr:outcomeId>g3rJfThPx5U</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>82000</gtr:amountPounds><gtr:country>Australia, Commonwealth of</gtr:country><gtr:currCode>AUD</gtr:currCode><gtr:currCountryCode>Australia</gtr:currCountryCode><gtr:currLang>en_AU</gtr:currLang><gtr:department>National Health and Medical Research Council</gtr:department><gtr:description>Supervisor on Clinical Research traning Fellowship</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Australian Government</gtr:fundingOrg><gtr:id>49ABB0C9-F46D-4011-848F-19ADD0ED7756</gtr:id><gtr:outcomeId>M3DLDVLBi8j</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>236000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Training Fellowship</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BC30EF08-09F1-4A91-AE18-629C385BEB3F</gtr:id><gtr:outcomeId>VnPjqRaPvFH0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCLH Clinical Research and Development Committee (CRDC) Clinician Scientist Fellowship</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>University College London Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>1C228A05-CF45-4CA4-88C7-31262CE1029E</gtr:id><gtr:outcomeId>7B6D74F2B580</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>245000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Research Training Fellowship</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D3D7CD51-AEDC-405B-8242-44AA00AA4DFA</gtr:id><gtr:outcomeId>F6F9F5DE24E0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinician Scientist Starter Grant</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>FF23C869-E97B-4295-BB1D-1788EC7C3E8D</gtr:id><gtr:outcomeId>QgQRrfhKdRZ0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>University College London Hospitals Charity (UCLH)</gtr:department><gtr:description>Fast Track grant</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>University College London Hospital</gtr:fundingOrg><gtr:id>A06823A5-2418-420A-AB5B-BFEFC21B0ACF</gtr:id><gtr:outcomeId>i7TDHgnk23X</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New animal model/reagent available: Bim knockout HBV-specific CD8 in HBV transgenic mouse</gtr:description><gtr:id>3C36B516-E5E1-4A50-8F5F-88994F20F489</gtr:id><gtr:impact>NEw scientific findings, not yet published</gtr:impact><gtr:outcomeId>qcrbKb7bwe7</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Bim knockout in HBV transgenic</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>558BED75-4FFB-4FB9-AF7A-D36C81DC2D2E</gtr:id><gtr:title>Licensing virus-specific T cells to secrete the neutrophil attracting chemokine CXCL-8 during hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f8dc2ebc70eda0b46fe7ca7cb568be2"><gtr:id>7f8dc2ebc70eda0b46fe7ca7cb568be2</gtr:id><gtr:otherNames>Gehring AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>HygFrcoxFbM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21DBD9EA-63F9-4BF8-A015-A3E25565AA90</gtr:id><gtr:title>Pathogenesis of hepatitis B virus infection and potential for new therapies.</gtr:title><gtr:parentPublicationTitle>British journal of hospital medicine (London, England : 2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a204313f8b28cda4fa83ec02826e3c1c"><gtr:id>a204313f8b28cda4fa83ec02826e3c1c</gtr:id><gtr:otherNames>Peppa D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1750-8460</gtr:issn><gtr:outcomeId>pm_16010_20_23124289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80D05385-AE8C-4484-9875-02B96937A308</gtr:id><gtr:title>Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76183b379cf986c149f52dd20886bd52"><gtr:id>76183b379cf986c149f52dd20886bd52</gtr:id><gtr:otherNames>Schurich A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>LZtFbMiBBnU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8935095B-124C-4C8A-961C-9407B205CCE1</gtr:id><gtr:title>Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7899ea19d47dbd497f60b7b9b5ecc23c"><gtr:id>7899ea19d47dbd497f60b7b9b5ecc23c</gtr:id><gtr:otherNames>Micco L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_16010_20_23046671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F02467DD-DD9D-4371-83F3-B2E24FB1A6A7</gtr:id><gtr:title>IL-2tissue-resident T cells in the human liver: Sentinels for hepatotropic infection.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/485941e1f06b626bfb30229fc4b3d280"><gtr:id>485941e1f06b626bfb30229fc4b3d280</gtr:id><gtr:otherNames>Pallett LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>5a2fd3375413b7.03148517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F1BFE60-F28F-4AB9-846B-5914BFC3FE98</gtr:id><gtr:title>IL-2-engineered nano-APC effectively activates viral antigen-mediated T cell responses from chronic hepatitis B virus-infected patients.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23f3c52fe5d543eeac44c3179f5ecda0"><gtr:id>23f3c52fe5d543eeac44c3179f5ecda0</gtr:id><gtr:otherNames>Liu M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_16010_20_22210908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3F508AD-7BBC-4E26-896D-230AA49B5297</gtr:id><gtr:title>Hepatitis B infection: current concepts and future challenges.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76c7e7f6d167384202514d2509288582"><gtr:id>76c7e7f6d167384202514d2509288582</gtr:id><gtr:otherNames>Nebbia G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>pm_16010_20_22252919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>121F984A-AB1E-453E-93BA-A7D89801C0C1</gtr:id><gtr:title>The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76183b379cf986c149f52dd20886bd52"><gtr:id>76183b379cf986c149f52dd20886bd52</gtr:id><gtr:otherNames>Schurich A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_16010_20_23516358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D9A21D3-FCF1-4BB8-895A-A3D0467E2E84</gtr:id><gtr:title>Temporal analysis of early immune responses in patients with acute hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a10439eb35b6873208116977e652748"><gtr:id>5a10439eb35b6873208116977e652748</gtr:id><gtr:otherNames>Dunn C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>iUegWUSWToS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>815B765E-EE68-448D-A429-D308CD6F282C</gtr:id><gtr:title>CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f69cf9b9a81fb26c178eafda2f64dbbd"><gtr:id>f69cf9b9a81fb26c178eafda2f64dbbd</gtr:id><gtr:otherNames>Hoare M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>PEetVWkBeWd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5613645A-82E3-48EF-B79C-F282F5FC792D</gtr:id><gtr:title>Platelets harness the immune response to drive liver cancer.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc11615f37418526ac40b69bc86fc1a4"><gtr:id>dc11615f37418526ac40b69bc86fc1a4</gtr:id><gtr:otherNames>Maini MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_16010_20_22826219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F328FCA4-C79B-451F-B04B-B2A2D283738C</gtr:id><gtr:title>Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f8dc2ebc70eda0b46fe7ca7cb568be2"><gtr:id>7f8dc2ebc70eda0b46fe7ca7cb568be2</gtr:id><gtr:otherNames>Gehring AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>SrZdUh5sm5z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D363A40-CCF9-4A07-B2ED-BF38F3DCF32D</gtr:id><gtr:title>Defective natural killer cell anti-viral capacity in paediatric HBV infection.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52960d2a25ccfec0c8413c520692cebd"><gtr:id>52960d2a25ccfec0c8413c520692cebd</gtr:id><gtr:otherNames>Heiberg IL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>544ffa414b8a89.75448534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>173F4A35-AB17-446D-81E3-C5388AFC0781</gtr:id><gtr:title>The host-pathogen interaction during HBV infection: immunological controversies.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e2d454ca16d8a9c35255be54ef78b2a"><gtr:id>7e2d454ca16d8a9c35255be54ef78b2a</gtr:id><gtr:otherNames>Bertoletti A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>EMo1zezA1U5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDCBC5DB-2C74-4886-851A-A8A15A616BBB</gtr:id><gtr:title>Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a204313f8b28cda4fa83ec02826e3c1c"><gtr:id>a204313f8b28cda4fa83ec02826e3c1c</gtr:id><gtr:otherNames>Peppa D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>HhhoGzNxCWf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7892FA1-4745-4101-9CDF-0E840EEEE8D3</gtr:id><gtr:title>Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76c7e7f6d167384202514d2509288582"><gtr:id>76c7e7f6d167384202514d2509288582</gtr:id><gtr:otherNames>Nebbia G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16010_20_23112829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2EC9D37-9BE0-4B89-9F90-2108A9510B2B</gtr:id><gtr:title>The molecular basis of the failed immune response in chronic HBV: therapeutic implications.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc11615f37418526ac40b69bc86fc1a4"><gtr:id>dc11615f37418526ac40b69bc86fc1a4</gtr:id><gtr:otherNames>Maini MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>XtXu5GNmeGY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A20E681A-EF2C-4BE2-A929-33A8EBBB4EFE</gtr:id><gtr:title>Living in the liver: hepatic infections.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8c35cfa45c5169539fa6d8e833e539f"><gtr:id>c8c35cfa45c5169539fa6d8e833e539f</gtr:id><gtr:otherNames>Protzer U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>pm_16010_20_22362353</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF1E7973-8897-400F-AA1C-245262E8D74E</gtr:id><gtr:title>IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d10e93066e667cdd76d1e66f25e5b519"><gtr:id>d10e93066e667cdd76d1e66f25e5b519</gtr:id><gtr:otherNames>Das A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_16010_20_22972930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E314BBA-E02B-41C6-BB40-5C990F5C2739</gtr:id><gtr:title>Rare inborn errors associated with chronic hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23cef8273e6a732f1e1851e6a9ba44ac"><gtr:id>23cef8273e6a732f1e1851e6a9ba44ac</gtr:id><gtr:otherNames>Zhao Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_16010_20_22610944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B1DB06D-DBE5-4079-814C-B68E7FB6622C</gtr:id><gtr:title>Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/485941e1f06b626bfb30229fc4b3d280"><gtr:id>485941e1f06b626bfb30229fc4b3d280</gtr:id><gtr:otherNames>Pallett LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>5675e43b16558</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B47D5B5-F173-4F52-B200-420A0323E846</gtr:id><gtr:title>Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a204313f8b28cda4fa83ec02826e3c1c"><gtr:id>a204313f8b28cda4fa83ec02826e3c1c</gtr:id><gtr:otherNames>Peppa D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>pm_16010_20_23254287</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801213</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>